Age as a prognostic factor in recurrent breast cancer.

The effect of age as a prognostic factor in recurrent breast cancer was studied in 1,168 patients treated on Eastern Cooperative Oncology Group (ECOG) protocols. Survival was significantly shorter in patients less than 35 years of age (P = .03). This was true even when other good prognostic factors were present. Eighteen prognostic factors were analyzed, and the effect on survival in each of six age groups was studied. Patients with better performance status, less than three sites of metastases, and without visceral or nodal metastases had a better survival time. A Cox proportional hazards model of survival showed that younger age groups, irrespective of menopausal status, had shorter survival times. The predicted median survival times after the first recurrence were 491 days for patients less than 35 years of age, 590 days for patients 36 to 45 years of age, and 700 days for those greater than 45 years of age.

Download Full-text

Significant survival improvement and prognostic factors of recurrent breast cancer after approval third generation aromatase inhibitors and trastuzumab

The Breast ◽

10.1016/j.breast.2011.08.093 ◽

2011 ◽

Vol 20 ◽

pp. S43-S44

Author(s):

Mayumi Ishida ◽

Shinji Ohno ◽

Sayaka Kuba ◽

Kazuhiro Tanaka ◽

Chinami Koga ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Aromatase Inhibitors ◽

Recurrent Breast Cancer ◽

Third Generation ◽

Significant Survival ◽

Recurrent Breast

Download Full-text

Prognostic Factors for Recurrent Breast Cancer: Univariate and Multivariate Analyses Including Histologic Grade and Amplification of the c-erbB-2 Protooncogene

Japanese Journal of Clinical Oncology ◽

10.1093/oxfordjournals.jjco.a039557 ◽

1992 ◽

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Multivariate Analyses ◽

Recurrent Breast Cancer ◽

Histologic Grade ◽

Recurrent Breast

Download Full-text

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BMC Cancer ◽

10.1186/s12885-021-09112-9 ◽

2022 ◽

Vol 22 (1) ◽

Author(s):

Shigemasa Takamizawa ◽

Tatsunori Shimoi ◽

Natsuko Satomi-Tsushita ◽

Shu Yazaki ◽

Toshihiro Okuya ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Progression Free Survival ◽

Recurrent Breast Cancer ◽

Neutrophil To Lymphocyte Ratio ◽

Cancer Center ◽

Lymphocyte Ratio ◽

Lymphocyte To Monocyte Ratio ◽

Third Line ◽

Recurrent Breast

Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabine in this setting, and prognostic factors are needed to guide appropriate treatment selection. The neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor for eribulin-treated patients, although it is unclear whether it is a prognostic factor for capecitabine-treated patients. Therefore, we analysed the ability of the NLR to predict oncological outcomes among patients who received capecitabine after previous anthracycline or taxane treatment for breast cancer. Methods We retrospectively reviewed the medical records of patients with metastatic or recurrent breast cancer who had previously received anthracycline or taxane treatment at the National Cancer Center Hospital between 2007 and 2015. Patients were included if they received eribulin or capecitabine monotherapy as first-line, second-line, or third-line chemotherapy. Analyses of overall survival (OS) and progression-free survival (PFS) were performed according to various factors. Results Between 2007 and 2015, we identified 125 eligible patients, including 46 patients who received only eribulin, 34 patients who received only capecitabine, and 45 patients who received eribulin and capecitabine. The median follow-up period was 19.1 months. Among eribulin-treated patients, an NLR of <3 independently predicted better OS. Among capecitabine-treated patients, an NLR of <3 independently predicted better PFS but not better OS. In addition, a lymphocyte-to-monocyte ratio of ≥5 was associated with better PFS and OS. Conclusions To the best of our knowledge, this is the first study to evaluate whether the NLR is a prognostic factor for capecitabine-treated patients with metastatic or recurrent breast cancer. However, the NLR only independently predicted PFS in this setting, despite it being a useful prognostic factor for other chemotherapies.

Download Full-text

Assessment of predictors and prognostic factors for locoregional recurrent breast cancer

International Surgery Journal ◽

10.18203/2349-2902.isj20185489 ◽

2018 ◽

Vol 6 (1) ◽

pp. 287

Author(s):

Hossam A. Elfol ◽

Tarek M. Rageh ◽

Mohammed A. Hamed

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Safety Margin ◽

Radical Mastectomy ◽

Recurrent Breast Cancer ◽

Oral Contraceptive Pills ◽

Female Patients ◽

History Of ◽

Recurrent Breast ◽

Locoregional Recurrent Breast Cancer

Background: Assessment of predictors and prognostic factors of locoregional recurrent breast cancer will help in management of those patients. The aim of this study was to assess and identify the predictors and prognostic factors for locoregional current breast cancer.Methods: This prospective study will be carried out on 50 female patients with history of breast cancer underwent surgical procedures either modified radical mastectomy (MRM) or conservative breast surgery (CBS) and adjuvant therapy (chemotherapy, radiotherapy, hormonal therapy).Results: Significant relationship between recurrence of breast cancer and Oral contraceptive pills of the studied female patients with history of breast cancer underwent surgery.Conclusions: Number of positive lymph nodes, lympho-vascular invasion, positive safety margin and presence of extensive intra-ductal component all these factors increase risk of recurrent breast cancer.

Download Full-text